International Stem Cell Corporation , a California-based biotechnology company developing novel stem cell based therapies and biomedical products, announced today preclinical data from its Parkinson's disease program. ISCO's Chief Scientific Officer Ruslan Semechkin, Ph.D., will discuss the data at the "Advances Through Stem Cell Research" press conference at the Society for Neuroscience's annual meeting at 10 a.m. on Nov. 18 in Washington, D.C. The preclinical data will form the basis for the Company's regulatory submission for its Phase 1 study in Parkinson's disease.
http://ift.tt/1xM8cE8
http://ift.tt/1xM8cE8
No comments:
Post a Comment